By Katherine Hamilton
Lisata Therapeutics shares dropped after a pancreatic cancer treatment trial didn't show significant improvement in patient survival.
The stock fell 32% to $2.64 on Wednesday, losing all its gains over the past month.
The Phase 2 trial studied the efficacy of certepetide as a treatment for pancreatic cancer. There was no significant improvement in median progression-free survival, which was five and a half months for both treated and placebo groups, the company said.
Preliminary results did show treated patients survived about 12.7 months compared with 9.7 months in the placebo group.
Lisata plans to advance certepetide development to Phase 3 in 2026, it said.
Write to Katherine Hamilton at katherine.hamilton@wsj.com
(END) Dow Jones Newswires
January 22, 2025 13:58 ET (18:58 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。